Important announcements for Hong Kong stocks yesterday and this morning: 1) Company News
1) Company News
$CHINA RES LAND (01109.HK)$From January to May, the cumulative contract sales were RMB 92.7 billion, a decrease of 35.3% year-on-year; rental income from operating real estate was RMB 11.77 billion, an increase of 16.5% year-on-year.
$Q TECH (01478.HK)$In May, the sales volume of mobile phone camera modules was 39.246 million, a decrease of 3.8% month-on-month and an increase of 35% year-on-year; the total sales volume of camera modules was 40.19 million, a decrease of 3.3% month-on-month and an increase of 35.8% year-on-year; the total sales volume of fingerprint recognition modules was 10.512 million, an increase of 10% month-on-month and an increase of 20.9% year-on-year.
According to the announcement, the development of business of mid-to high-end camera module products and automotive camera module products was good, mainly due to the recovery of demand in the smart phone market and the increase in market share.
$ZHIHU-W (02390.HK)$In the first quarter, the total revenue was RMB 961 million, and the gross margin increased to 56.6%. The average monthly active users during the period were 89 million, and the average monthly subscription members were 14.8 million.
$EC HEALTHCARE (02138.HK)$Preeminent Medical Centre Limited plans to sell 51% of the equity for HKD 80.249 million, a discount of about 5% compared to the acquisition price.
$GOFINTECH INNOV (00290.HK)$It plans to acquire 4.2726% equity in Shenzhen Quanten Technology Co., Ltd. for HKD 39.5 million. The target company is mainly engaged in R&D, production and sales of quantum computers. It is one of the few companies in the world that can develop and produce complete sets of quantum computers. Its patented technology and products include superconducting quantum chip computers, desktop nuclear magnetic quantum computers, quantum computing application algorithms, cloud platform technology, etc.
$Livzon Pharmaceutical Group Inc.(01513.HK)$
$LIVZON PHARMA (01513.HK)$$Junshi Biosciences Co Ltd(01877.HK)$
The new indication of Tyvyt (Sintilimab injection) for first-line treatment of extensive-stage small cell lung cancer was approved for marketing. In addition, the product "Gadoteric Acid Injection" in the field of medical imaging has been approved for marketing.
$JUNSHI BIO (01877.HK)$The revenue from the main business in May was HKD 30.9 million, a decrease of 35.7% year-on-year and a decrease of 10.5% month-on-month.
$SINO BIOPHARM (01177.HK)$$HKR International Ltd.(00480.HK)$
$SIM TECH (02000.HK)$: In May, the revenue of the main business was HKD 30.9 million, a decrease of 35.7% year-on-year and a decrease of 10.5% month-on-month.
$HKR INT'L (00480.HK)$: It is expected to obtain a shareholder's loss of approximately HKD 460 million for the 2024 fiscal year.
$GLOBAL SWEET (03889.HK)$: It is estimated that the net profit for the first half of the year will be approximately HKD 130 million to HKD 170 million, turning losses into gains year-on-year.
$MICROPORT (00853.HK)$: All convertible bonds with a total principal amount of USD 700 million due in 2026 have been fully redeemed and cancelled.
2) Repurchase Dynamics
$TENCENT (00700.HK)$: Spend HKD 1.004 billion to buy back 2.7 million shares, with a repurchase price range of HKD 369.8-376.8 per share.
$MEITUAN-W (03690.HK)$: Spend approximately HKD 500 million to buy back 4.3953 million shares, with a repurchase price range of HKD 112.5-116.6 per share.
$AIA (01299.HK)$: Spend HKD 424 million to buy back 7.5352 million shares, with a repurchase price range of HKD 55.85-56.50 per share.
$XIAOMI-W (01810.HK)$: Spend HKD 48.0175 million to buy back 2.8 million shares, with a repurchase price range of HKD 17.04-17.20 per share.
$HANG SENG BANK (00011.HK)$: Spend approximately HKD 31.8089 million to buy back 300,000 shares, with a repurchase price range of HKD 105-106.5 per share.
$CK ASSET (01113.HK)$: Spend HKD 30.0348 million to buy back 1 million shares, with a repurchase price range of HKD 29.90-30.15 per share.
$TECHTRONIC IND (00669.HK)$: Spend HKD 23.5976 million to buy back 250,000 shares, with a repurchase price range of HKD 94.15-94.7 per share.
$FENBI (02469.HK)$: Spend HKD 13.4571 million to buy back 3.1415 million shares, with a repurchase price range of HKD 4.23-4.37 per share.
$CHINASOFT INT'L (00354.HK)$: Spend HKD 11.2495 million to buy back 2.812 million shares, with a repurchase price range of HKD 3.98-4.01 per share.
$MGM CHINA (02282.HK)$: Spend HKD 11.1166 million to buy back 800,000 shares, with a repurchase price range of HKD 13.5-14.26 per share.
Editor/tolk
